WSJ What’s News

A.M. Edition for June 2. Google parent Alphabet plans to issue $80 billion in equity this year to pay for its massive spending tied to the AI race. Plus, California voters head to the polls in a closely-watched primary to choose Governor Gavin Newsom’s successor. And WSJ foreign correspondent Stephen Kalin details a new demand by President Trump complicating efforts to negotiate an end to the Iran war: that Arab states establish diplomatic relations with Israel. Luke Vargas hosts.

Sign up for the WSJ’s free What’s News newsletter.

Learn more about your ad choices. Visit megaphone.fm/adchoices

P.M. Edition for June 1. AI giant Anthropic has confidentially filed paperwork to go public, potentially as soon as this fall. WSJ Heard on the Street writer Asa Fitch discusses why it matters whether Anthropic or rival OpenAI make their stock market debut first. Plus, the Trump administration is signaling a retreat on its $1.8 billion “anti-weaponization” fund, which met powerful pushback from members of Congress.

And the top two movies at the box office this weekend were horror films made by Gen Z filmmakers. We hear from Journal entertainment reporter Ben Fritz about whether this represents a new pathway for Hollywood hits. Alex Ossola hosts.

Sign up for the WSJ's free What's News newsletter.

Learn more about your ad choices. Visit megaphone.fm/adchoices

A.M. Edition for June 1. Nvidia unveils a next generation lineup of laptops and desktops designed to run AI agents. Plus, SoftBank leapfrogs Toyota to become Japan's most valuable company on news it will invest more than $50 billion in data centers in France. And Colombia lurches right, as voters back a presidential candidate pledging a major drugs crackdown. WSJ South America bureau chief Juan Forero says a potential win by firebrand Abelardo de la Espriella in a runoff later this month could hand President Trump another close ally in Latin America. Luke Vargas hosts.

Sign up for the WSJ’s free What’s News newsletter.

Learn more about your ad choices. Visit megaphone.fm/adchoices

Flawless skin. Thicker hair. A snatched jawline. Better sleep. These are some of the benefits social media users claim peptides can deliver. But many of these uses are not FDA-approved, and consumers are increasingly turning to the grey market. WSJ’s Sara Ashley O’Brien, who covers the business and culture of wellness, joins host Alex Ossola to discuss the reality behind the hype and the risks involved.

Further Reading

The Explosive Rise of Unapproved Peptide Injections

Teen Boys and Young Men Are Injecting Peptides in Search of Perfection

Learn more about your ad choices. Visit megaphone.fm/adchoices

Are memory chips the new oil? And why are energy stocks getting the cold shoulder? Plus, how is Ford cashing in on the AI boom? Imani Moise discusses the biggest stock moves of the week and the news that drove them.

Sign up for the WSJ's free Markets A.M. newsletter.

Learn more about your ad choices. Visit megaphone.fm/adchoices